Shionogi last month signed a basic agreement to sell the drug to the Japanese government. - Reuters
TOKYO (Reuters): Shares of Shionogi & Co plunged in Tokyo trading on Wednesday (April 13) amid concerns that the drugmaker's oral treatment for Covid-19, which is still awaiting approval from regulators, could pose pregnancy risks.
Shionogi does not recommend use of the pill during pregnancy based on the preclinical data showing a link to birth defects, the company said through a spokesperson.
Already a subscriber? Log in.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
